Thursday, September 3, 2015

Some Medicare drug plans improved star ratings, study says

Twenty eight percent of Medicare Advantage plans and 49 percent of stand-alone Part D plans improved their star ratings from 2012 to 2013, according to an analysis by Avalere Health of data released Centers for Medicare & Medicaid Services.

Some Medicare drug plans improved star ratings, study says

0 comments

Twenty eight percent of Medicare Advantage (MA) plans and 49 percent of stand-alone Part D plans (PDPs) improved their star ratings from 2012 to 2013, according to an analysis by Avalere Health of data released Centers for Medicare & Medicaid Services’ (CMS).

“This is good news for Medicare beneficiaries,” Bonnie Washington, Avalere senior vice president, said in a statement. “In 2013, beneficiaries will be able to choose from a greater number of high-quality plans that best meet their health care needs.”

Avalere said that of the 419 Medicare Advantage plan contracts that received star ratings in both 2012 and 2013, 119 improved their star ratings in 2013. The study said that 50 Medicare Advantage plan contracts had lower ratings in 2013 as compared to 2012. For prescription drug plans, of the 59 PDP contracts that received ratings in both 2012 and 2013, 29 improved their star ratings while six saw a decline.

A link to the Avalere Health news release is here.

0 comments
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy:

Philly.com comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by Philly.com staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
 
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at dsell@phillynews.com or 215-854-4506.

David Sell
Also on Philly.com:
letter icon Newsletter